It’s Tuesday, and after yesterday’s nice little uptick in the Nasdaq (+1.5%), S&P 500 (+1.0%), and Dow (+0.3%), the market seems to be singing a different tune going into this morning’s opening bell. 

Now whether that momentum continues into today’s trading, only time will tell.  But with Crowdstrike’s massive victim’s list and the seismic shift in the political landscape, volatility is definitely in the air… 

Which is why, if there’s one image of volatility that sends as much dopamine to my brain as my love for my wife and kids, it’s this: 

(Source: My Personal TradingView Chart) 

It’s a beauty isn’t it? 

This my friends is MIRA Pharmaceuticals (NASDAQ:MIRA), and as yesterday’s big swinging “blue” bar shows, Mira investors were living the life with their shares skyrocketing nearly 627.25% in yesterday's trading. 

(Source: Google Finance) 

But why the sudden explosion in Mira’s stock? Well according to reports, it all stems from some highly encouraging preclinical trial results for their new drug, Ketamir-2.

(Source: Yahoo Finance) 

This latest announcement has thrust this under the radar pharma company into the spotlight, as new data revealed their novel oral ketamine analog, Ketamir-2, is showing significant promise when treating several neurological and neuropsychiatric disorders. Including advanced treatment for depression, treatment-resistant depression, and post-traumatic stress disorder (PTSD). So clearly, all the good things that you’d want from a healthy neurological standpoint. 

(Source: Giphy) 

Now obviously when it comes to pharma companies, this is massive. But what’s interesting is that prior to the announcement, Mira was trading at a measly 69 cents from its Friday close. By yesterday afternoon, it had shot up to $5.01 as trading volume exploded with more than 116 million shares trading hands - making their daily average of about 654,000 shares look like a chump. 

(Source: Market Watch) 

But while many investors saw the word “retirement” run through their heads due to this seismic green day, what makes Ketamir-2 stand out from other neurological solutions? 

Good question. For one, it boasts an impressive oral bioavailability rate of about 80%, significantly higher than the less than 30% seen with traditional ketamine. Meaning Mira’s breakthrough looks to result in higher efficacy at lower doses. Not bad at all.

(Source: Imgflip) 

For all you biology enthusiasts, Ketamir-2 also appears to bypass the mu-opioid receptor, potentially reducing the risk of opioid-related side effects and dependency issues. In layman's terms, Ketamir-2 doesn’t mess with the part of the brain involved with opioid addiction, which means less dependency and less risk of addiction… aka the most impressive part of the drug. 

(Source: Giphy) 

In fact, Mira’s chairman and CEO, Erez Aminov, echoed the optimist as he stated, “Our vision at MIRA is to transform the treatment landscape for neurological and neuropsychiatric disorders. Ketamir-2 shows great promise in addressing these debilitating conditions with improved efficacy and safety, offering new hope and better quality of life for patients and their families." 

(Source: Mira Pharmaceuticals) 

Yet, while it seems like this big pharma company has cracked the code to depression and PTSD, Mira isn’t stopping there. 

According to reports, the company is also investigating Ketamir-2’s potential for treating chemotherapy-induced depression, cancer-related neuropathic pain, and even looking into orphan drug indications for conditions like multiple sclerosis-induced depression and Huntington’s disease-induced depression. So clearly the company has a chip on its shoulder…

And with Mira making a significant leap forward with Ketamir-2, it’s only fueling that chip to take it further in the pharmaceutical world. 

(Source: Giphy) 

So with that said, for those investors who got a piece of this massive 627.35% explosion yesterday, congrats (I’m jealous). For those who are just catching wind of this, take note on how $MIRA reacted to the positive data from its preclinical trials. 

(Source: Giphy) 

Because if it responds this well to preclinicals… just think how explosive it’ll be when they go onward through the rest of the Phases. In the meantime, the question remains: could this stock keep running today or has it fatigued for now? 

Only time will tell, but for now, keep an eye on this stock. There may still be some more leg room to run for all you “fashionably late” investors. But hey, like I’ve said before, what the heck do I know? I’m just the messenger here… (as I slowly fall into the abyss of love while gazing at Mira’s massive blue candle on my tradingview chart). 

(Source: Giphy) 

Stocks.News doesn't hold any positions in companies mentioned.